News - Page 131 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index

Post published:December 13, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

Post published:December 13, 2021
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: November 2021

Psychedelic Research Bulletin: November 2021

Post published:December 12, 2021
Post category:Psychedelics Research Review

Read more about the article Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds

Psychedelic Bulletin: Our Dispatch from Horizons NYC; NIDA to Study Delix Compounds

Post published:December 10, 2021
Post category:Psychedelic Bulletin

Read more about the article Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives

Post published:December 9, 2021
Post category:Press Release

Numinus Wellness Inc. Reports Q4 and Year End 2021 Results

Post published:December 9, 2021
Post category:Press Release

Read more about the article atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain

atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai’s supply chain

Post published:December 9, 2021
Post category:Press Release

Read more about the article MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System

Post published:December 9, 2021
Post category:Press Release

Read more about the article Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Post published:December 8, 2021
Post category:Press Release

Read more about the article Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder

Post published:December 8, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.